Haloperidol Krka

Haloperidol Krka is a prescription‑only medication that contains the active ingredient haloperidol. It is supplied in an intravenous formulation, with strength not specified in the available data, and is marketed in the European Union. Haloperidol belongs to the butyrophenone class of antipsychotics and works as a dopamine D2 receptor antagonist. The product is used under supervision for psychiatric conditions. Psychiatrists or physicians experienced in managing psychotic disorders may prescribe it.

Haloperidol Krka is indicated for the management of several acute and chronic psychiatric conditions where dopamine blockade is therapeutic.

- Schizophrenia, including acute exacerbations - Acute psychotic episodes associated with mood disorders - Mania in bipolar disorder when rapid symptom control is required - Severe agitation or aggression that poses a risk to the patient or others - Adjunctive treatment of delirium in intensive‑care settings (off‑label in some regions)

Side effects of haloperidol may vary in frequency and severity; they are categorized as common or serious.

Common: - Drowsiness or sedation - Extrapyramidal symptoms such as tremor, rigidity, or akathisia - Dry mouth or increased salivation

Serious: - Neuroleptic malignant syndrome - Tardive dyskinesia - QT interval prolongation leading to arrhythmias

When prescribing Haloperidol Krka, clinicians should evaluate patient history and monitor for specific safety concerns.

- Assess for cardiovascular disease, especially prolonged QT interval - Review history of movement disorders or Parkinsonian symptoms - Use caution in patients with hepatic or renal impairment - Monitor for signs of infection or blood dyscrasias - Evaluate pregnancy status; benefits must outweigh potential risks - Avoid abrupt discontinuation to reduce withdrawal phenomena

Haloperidol can interact with other medications, altering its effectiveness or increasing adverse effects.

Avoid: - Other dopamine antagonists or antipsychotics, which may amplify extrapyramidal effects - Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) - Strong CYP3A4 inhibitors such as ketoconazole or erythromycin, which raise haloperidol levels

Use with caution: - CYP3A4 inducers like rifampin or carbamazepine, which may reduce efficacy - Central nervous system depressants (benzodiazepines, opioids) that increase sedation - Anticholinergic agents that may mask extrapyramidal symptoms